The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Companion FOA: PAR-22-028 , X01 Resource Access Program
Deadlines:
-
Letter of Intent Due Date(s): 30 days prior to the application due date.
-
Application Due Dates: Dec. 22, 2021; Feb. 9, 2022; June 9, 2022; Oct. 8, 2022; Feb 8, 2023; June 9, 2023; Oct 10, 2023; Feb 8, 2024; June 7, 2024; Oct. 10, 2024
PAR-22-030 Expiration Date October 11, 2024 per issuance of NOT-NS-24-020(Original Expiration Date: June 08, 2024 )